Donald W. Light
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald W. Light has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Joel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
2 shared publicationsRebecca Warburton
2 shared publicationsJoel R Lexchin
York University School of Health Policy and Management, Toronto, Ontario, Canada
1 shared publication- Jon Kim Andrus
Pan American Health Organization, 525 23rd Street, NW, Washington, DC 20037, USA
1 shared publication Michael Dixon
NHS Alliance, Retford, Nottinghamshire, DN22 6JD
1 shared publicationMélanie Terrasse
Department of Sociology, Princeton University, Princeton, NJ, USA
1 shared publication
Latest Publications
- 12 June 2017
- Published by Taylor & Francis in Journal of Ethnic and Migration Studies
- Vol. 43 (12) , 1985-2002
Immigrant access in the Affordable Care Act: legacies of the Confederacy
During its first five years, the Affordable Care Act (ACA) built upon previous categorical distinctions among immigrants to solidify some inequalities and partially redress others. To analyse these changes, we build upon Tilly’s theory of durable inequalities by adding the concepts of redress and retrenchment, reflecting the dynamics of change among countervailing powers in a policy field. We employ this theoretical framework to investigate the ways the ACA has selectively reduced barriers for certain categories of immigrants, but not others. Some of these strategies date back to the ways the white power elite in Confederate states set out to regain control as Congress acted after 1865 to grant freed slaves full citizen’s rights. These barriers became blueprints for political strategies to block or subvert federal reforms. Additionally, we describe the ACA effort to reduce the legacy of de facto barriers for immigrants. We also detail how the federalist nature of the Act continued to allow wide-ranging forms of retrenchment and redress at state and local levels. Through this theoretical and historical analysis, we show how the ACA sought to redress certain historical inequalities of immigrant health care access but also solidified others, particularly in the case of undocumented immigrants.
- 12 June 2017
- Published by Taylor & Francis in Journal of Ethnic and Migration Studies
- Vol. 43 (12) , 1985-2002
Immigrant access in the Affordable Care Act: legacies of the Confederacy
During its first five years, the Affordable Care Act (ACA) built upon previous categorical distinctions among immigrants to solidify some inequalities and partially redress others. To analyse these changes, we build upon Tilly’s theory of durable inequalities by adding the concepts of redress and retrenchment, reflecting the dynamics of change among countervailing powers in a policy field. We employ this theoretical framework to investigate the ways the ACA has selectively reduced barriers for certain categories of immigrants, but not others. Some of these strategies date back to the ways the white power elite in Confederate states set out to regain control as Congress acted after 1865 to grant freed slaves full citizen’s rights. These barriers became blueprints for political strategies to block or subvert federal reforms. Additionally, we describe the ACA effort to reduce the legacy of de facto barriers for immigrants. We also detail how the federalist nature of the Act continued to allow wide-ranging forms of retrenchment and redress at state and local levels. Through this theoretical and historical analysis, we show how the ACA sought to redress certain historical inequalities of immigrant health care access but also solidified others, particularly in the case of undocumented immigrants.
- 9 July 2015
- Published by Springer Nature in Society
- Vol. 52 (4) , 384-386
Doctors Without Borders
Why do cancer drugs get such an easy ride?
Rushed approvals result in a poor deal for both patients and cancer research Unlike most other diseases, cancer instils a special fear and “is treated as an evil, invincible predator, not just a disease.”1 The ability of drug companies to charge very high prices, even when most approved cancer drugs provide little gain for patients, drives much of the research, as desperate patients lead some governments and private insurers to pay whatever companies charge. Officials within the US Food and Drug Administration are enthusiastic about new cancer drugs. Richard Pazdur, who oversees oncology activities for the FDA says that new cancer drugs are so effective that “We don’t have a lot of questions on [these] drugs because they’re slam dunks. It’s not if we’re going to approve them. It’s how fast we’re going to approve them.”2 The methodological weaknesses in oncology trials do not support such enthusiasm. Researchers compared 8942 oncology clinical trials conducted between 2007 and 2010 with trials for other diseases.3 Trials for cancer drugs were 2.8 times more likely not to be randomised, 2.6 times more likely not to use a comparator (single arm), and 1.8 …
Why do cancer drugs get such an easy ride?
Rushed approvals result in a poor deal for both patients and cancer research Unlike most other diseases, cancer instils a special fear and “is treated as an evil, invincible predator, not just a disease.”1 The ability of drug companies to charge very high prices, even when most approved cancer drugs provide little gain for patients, drives much of the research, as desperate patients lead some governments and private insurers to pay whatever companies charge. Officials within the US Food and Drug Administration are enthusiastic about new cancer drugs. Richard Pazdur, who oversees oncology activities for the FDA says that new cancer drugs are so effective that “We don’t have a lot of questions on [these] drugs because they’re slam dunks. It’s not if we’re going to approve them. It’s how fast we’re going to approve them.”2 The methodological weaknesses in oncology trials do not support such enthusiasm. Researchers compared 8942 oncology clinical trials conducted between 2007 and 2010 with trials for other diseases.3 Trials for cancer drugs were 2.8 times more likely not to be randomised, 2.6 times more likely not to use a comparator (single arm), and 1.8 …
- 1 December 2012
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 31 (12) , 2826-2828
Medicine In The Thrall Of The Culture Of DrugsPharmageddon By Healy David Berkeley (CA) : University of California Press , 2012 302 pp.; $39.95
- 1 December 2012
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 31 (12) , 2826-2828
Medicine In The Thrall Of The Culture Of DrugsPharmageddon By Healy David Berkeley (CA) : University of California Press , 2012 302 pp.; $39.95
Pharmaceutical research and development: what do we get for all that money?
Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones
Pharmaceutical research and development: what do we get for all that money?
Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones
- 1 January 2012
- Published by Taylor & Francis in Ethnic and Racial Studies
- Vol. 35 (1) , 23-39
Categorical inequality, institutional ambivalence, and permanently failing institutions: the case of immigrants and barriers to health care in America
I draw on the theories of Charles Tilly, Robert K. Merton, Eleanor Barber, Marshall Meyer, and Lynne Zucker to develop a three-part framework for understanding the organizational and institutional interface between social services like health care and disadvantaged minorities like immigrants. Tilly's theory of durable inequality is transposed to categorical inequalities in organizations and law. His vocabulary of motives is expanded to include categorical entrenchment, restitution, and compensation. These embedded inequalities lead to institutional ambivalence in the provision of services and to permanently failing institutions that work poorly, waste resources, or provide uneven quality, yet do not collapse but endure while resisting reform. One rationale for resistance is ‘moral hazard’ by individuals; but the theory of moral hazard is biased and partial, because provider moral hazard and insurer moral hazard are more prevalent. The specific manifestations of these concepts and dynamics between them warrant further research in different contexts.
- 1 January 2012
- Published by Taylor & Francis in Ethnic and Racial Studies
- Vol. 35 (1) , 23-39
Categorical inequality, institutional ambivalence, and permanently failing institutions: the case of immigrants and barriers to health care in America
I draw on the theories of Charles Tilly, Robert K. Merton, Eleanor Barber, Marshall Meyer, and Lynne Zucker to develop a three-part framework for understanding the organizational and institutional interface between social services like health care and disadvantaged minorities like immigrants. Tilly's theory of durable inequality is transposed to categorical inequalities in organizations and law. His vocabulary of motives is expanded to include categorical entrenchment, restitution, and compensation. These embedded inequalities lead to institutional ambivalence in the provision of services and to permanently failing institutions that work poorly, waste resources, or provide uneven quality, yet do not collapse but endure while resisting reform. One rationale for resistance is ‘moral hazard’ by individuals; but the theory of moral hazard is biased and partial, because provider moral hazard and insurer moral hazard are more prevalent. The specific manifestations of these concepts and dynamics between them warrant further research in different contexts.
- 1 July 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (13) , 6-7
Drug R&D Costs Questioned
- 1 July 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (13) , 6-7
Drug R&D Costs Questioned
- 7 February 2011
- Published by Springer Nature in BioSocieties
- Vol. 6 (1) , 34-50
Demythologizing the high costs of pharmaceutical research
- 7 February 2011
- Published by Springer Nature in BioSocieties
- Vol. 6 (1) , 34-50
Demythologizing the high costs of pharmaceutical research
- 1 January 2011
- Published by Elsevier in Social Science & Medicine
- Vol. 72 (2) , 129-132
Historical and comparative reflections on the U.S. national health insurance reforms
- 1 January 2011
- Published by Elsevier in Social Science & Medicine
- Vol. 72 (2) , 129-132
Historical and comparative reflections on the U.S. national health insurance reforms